The Effect of Helicobacter Pylori Infection on Insulin Resistance and Pregnancy Outcomes in Patients with Gestational Diabetes Mellitus Authors: Maryam Rafiei, Farideh Movahed, Shokoh Abotorabi, Mohammadhosein Hoseinimotlaq Published: 2025 ABSTRACT Background:To investigate the association between Helicobacter pylori infection and insulin resistance and pregnancy outcomes in pregnant women with gestational diabetes mellitus (GDM).Materials and Methods:From 1st July 2020 to 31st August 2021, a prospective cohort study was conducted on 100 pregnant women with GDM based on 75 gr oral glucose tolerance test results between 24-28 weeks of gestation in Kowsar hospital—a tertiary teaching hospital in Qazvin province, Iran. All enrolled patients underwent testing for H. pylori serum IgG antibody and fasting insulin level. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) is computed using fasting blood sugar and fasting serum insulin level, and HOMA-IR ≥2.5 is considered an indicator of insulin resistance. The patient was followed till delivery and evaluated for the incidence of pregnancy complications, including preeclampsia, preterm labor (PTL), need for insulin therapy, and delivery of large for gestational age (LGA) and small for gestational age (SGA) neonates.Results:The frequency of H. pylori infection was 62%. H. pylori seropositivity was associated with elevated serum insulin level (15.88 ± 6.71 Vs 12.86 ± 5.69, P ˂ 0.05) and higher frequency of HOMA-IR ≥2.5 (83.87% Vs 63.16%, P < 0.05). In multivariate analysis, H. pylori seropositivity was the strongest risk factor for HOMA-IR ≥2.5 (OR = 3.263, 95% CI: 1.160- 9.176, P = 0.025). there was no association between H. pylori seropositivity and pregnancy outcomes. In this study, the frequency of LGA was higher among patients with HOMA-Ir ≥2.5 (36.9% Vs 5.7%, P ˂ 0.0001).Conclusion:H. pylori infection is prevalent among patients with gestational diabetes and is associated with insulin resistance in this group of pregnant women. INTRODUCTION Helicobacter pylori is a type of bacteria that is gram-negative, spiral-shaped, and microaerophilic. It is responsible for causing the most frequent human chronic bacterial infection, with an estimated worldwide prevalence of over 50%.[1] The bacterium triggers chronic inflammation and immune system responses in the stomach and gastrointestinal tract.[2] A recent meta-analysis has observed that the prevalence of H. pylori infection decreased in last decades from 58.2% to 43.1% and varies based on age groups, geographic region, and diagnostic methods. Younger age, living in high-income countries, or countries with high levels of universal health coverage are associated with a lower prevalence of H. pylori infection. use of serological diagnostic methods associated with higher H. pylori prevalence than non-serological methods.[3] The prevalence of H. pylori infection in pregnant women was assessed at 46% globally, ranging from 7.6% in Finland to 94% in Sudan between 2000 and 2012.[4] Although many people with H. pylori infection don’t experience any symptoms, research has shown a strong link between this infection and various gastrointestinal issues such as peptic ulcer disease, non-ulcer dyspepsia, gastric adenocarcinoma, and lymphoma. Furthermore, this infection has been associated with extra-intestinal consequences like coronary artery disease, iron deficiency anemia, and immune thrombocytopenia.[5] In pregnancy, H. pylori infection is associated with pre-eclampsia, gestational diabetes, fetal growth restriction, and hyperemesis gravidarum.[6] Several studies have investigated the association between H. pylori and insulin resistance and diabetes in non-pregnant individuals, although the results are contradictory.[789101112] H. pylori causes chronic inflammation and immune system responses in the stomach and gastrointestinal tract. This involves several inflammatory cytokines and adipokines, such as tumor necrosis factor α (TNF-α) and leptin.[13] Infected patients exhibit low leptin and high TNF-α, leading to insulin resistance compared to other populations.[14] There have been a few studies on the link between H. pylori infection and insulin resistance in pregnant individuals. However, there has been no research conducted on gestational diabetic patients. In 2018, Alshareef and his colleagues carried out a study in Sudan to investigate the relationship between H. pylori seropositivity and insulin resistance in pregnant women. The results showed no statistical association between the two factors.[15] Pregnancy is accompanied by insulin resistance due to placental secretion of diabetogenic hormones such as growth hormone, placental lactogen, and progesterone[16], which are not alterable. Hence, there is room for investigating another modifiable insulin resistance mechanism in gestational diabetic patients. The purpose of this study is to investigate the association between H. pylori infection and insulin resistance as a modifiable factor in pregnant patients with gestational diabetes. Proving such a correlation can lead to utilizing further interventions to reduce poor pregnancy outcomes associated with GDM. MATERIALS AND METHODS Study design A prospective cohort study was carried out on 100 pregnant women who had gestational diabetes mellitus (GDM) at Kowsar Teaching Hospital, a tertiary maternity center in Qazvin, Iran. The study was conducted from 1st July 2020 to 31st August 2021. All eligible participants who met the inclusion criteria and signed the informed consent form were enrolled in the study. The study included women who had a singleton viable pregnancy, were in their 24th to 28th week of gestation, and had recently been diagnosed with gestational diabetes. Patients with overt diabetes, hypertension, chronic kidney disease, hemoglobinopathies, a history of H. pylori treatment, and those who had received antibiotic therapy in the last six months were excluded from the study. Checklists recorded demographic features: age, gravidity, parity, gestational diabetes history, gestational age at diagnosis, pre-pregnancy BMI, and weight gain during the first and second trimesters. GDM was diagnosed based on the guidelines recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG), which state that a fasting blood glucose (FBG) level of ≥92 mg/dl or 1 h blood glucose level of ≥180 mg/dl and/or 2 h blood glucose level of ≥153 mg/dl, after a 75 gram oral glucose load.[1] Women who were diagnosed with gestational diabetes between 24 and 28 weeks of pregnancy underwent testing for H. pylori IgG titer and fasting insulin and glucose levels right after diagnosis, before any treatment was given. They were then monitored until delivery for various pregnancy outcomes, such as requiring insulin for controlling blood sugar levels, preeclampsia, preterm birth (delivery before 37 weeks), delivering a large for gestational age baby (weighing more than the 90th percentile for gestational age), or a small for gestational age baby (weighing less than the 10th percentile for gestational age). Follow-up visits were scheduled based on the national protocol for maternal care and adjusted according to the mother and fetus’ condition, if necessary. In this study, we used the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) as an index of insulin resistance. It was calculated using the following formula: (Glucose x Insulin) divided by 405 (Glucose unit: mg/dl). Although the optimal threshold for this index is not yet established, previous studies[2] have suggested that values above 2.5 may indicate insulin resistance. The glucose level was measured using the glucose oxidase method with the AUDIT commercial kit from Italy. Fasting insulin was measured using electrochemiluminescence assays with the Roche COBAS system from Germany. H. pylori IgG antibodies were tested using the H. pylori-specific ELISA kit from ImmunoLab, also from Germany. Five milliliters of blood were taken into a plain tube, allowed to clot, and then centrifuged at 4000 ×g. The samples were stored at −20°C. Test results equal to or greater than five units were considered positive. Statistical analyses Data analyses were conducted using SPSS statistics software package version 22(IBM Crop., Armonk, NY, USA). The normality of the distribution of data was checked using the Kolmogorov-Smirnov test. Quantitative variables were described using means and medians, while qualitative variables were described using frequencies and percentages. An independent T-test or its non-parametric equivalent, the Mann-Whitney U test and χ2, were used to compare the difference of medians and proportions between the H. pylori IgG seropositive and IgG seronegative groups. A P value of less than 0.05 was considered significant for all differences. RESULTS A total of 118 pregnant women with newly diagnosed GDM at 24-28 weeks gestation participated voluntarily in this prospective cohort study. Eighteen women lost their follow-up visit, and a total of 100 women were followed till delivery, the study’s endpoint. The mean age, gravidity, and gestational age at diagnosis of GDM were 32.29 ± 5.23 years, 2.08 ± 0.91, and 26.19 ± 1.72 weeks, respectively. Based on the results of the serological test, the frequency of H. pylori infection was 62 (62%). Table 1 summarizes the demographics of the patients. There were no significant differences between the seropositive and seronegative groups in terms of age, gravidity, parity, gestational age at GDM diagnosis, pre-pregnancy BMI, weight gain 1st and 2nd trimesters, and history of gestational diabetes. In this study. Table 1Baseline characteristics of the participants in two groupsCharacteristicsH. pylory IgG seropositivity P Yes (62) (Mean±SD)No (38) (Mean±SD)Age (year)32.17±532.47±5.640.969Gravidity2.17±0.941.92±0.850.170Parity0.93±0.760.76±0.780.198Gestational age at GDM diagnosis (weeks)26.11±1.6326.31±1.890.763Pre-pregnancy BMI (Kg/M2)26.84±4.7524.59±2.990.2271st and 2nd-trimester weight gain (Kg)8.69±5.469.03±5.520.706FBS (mg/dl)94.93±10.6795.55±12.570.802BS 1 h after 75 gr GLU (mg/dl)185.64±25.30182.24±34.300.595BS 2 h after 75 gr GLU (mg/dl)143.98±29.83140.87±34.470.649History of gestational diabetes17 (27.4%)5 (13.2%)0.168 Baseline characteristics of the participants in two groups H. pylori-positive patients had elevated serum insulin levels compared to their H. pylori-negative counterparts at 15.88 ± 6.71 vs. 12.86 ± 5.69 ratios. This difference was statistically significant (P < 0.05). In the H. pylori-positive group, 83.87% of patients (52 subjects) had HOMA-IR ≥2.5. this value in H. pylori-negative counterparts was 63.16% (24 subjects). This difference was statistically significant (P < 0.05). In multivariate analysis, maternal age, gestational age at GDM diagnosis, and H. pylori seropositivity were found to be predictors of HOMA-IR ≥2.5 in patients with GDM. After adjusting for these covariates, H. pylori seropositivity remained the strongest risk factor for HOMA-IR ≥2.5 with an odds ratio of 3.263 (95% CI: 1.160–9.176, P = 0.025) [Table 2]. Table 2Multivariate logistic regression analysis on predictors of HOMA-IR ≥2.5UnadjustedPredictors B S.E.WalddfSig.Exp(B)95% C.I. for EXP(B)LowerUpperAge1.1530.23424.23510.0003.1670.7900.965Gravid−0.3180.2481.64010.2000.7270.4471.184Parity−0.1910.2980.41310.5200.8260.4611.480Gestational age−0.3020.1394.71010.0300.7390.5630.971History of GDM−0.8470.6721.59110.2070.4290.1151.599Weight gain (1st and 2nd trimester)−0.0010.0430.00110.9760.9990.9181.087BMI0.0950.0652.13810.1441.1000.9681.2501st h BS0.0060.0080.56010.4541.0060.9901.0222nd h BS−0.0100.0071.80610.1790.9900.9761.005H.pylory1.1100.4825.30010.0213.0331.1797.802 Adjusted Age-0.1600.0577.91010.0050.8520.7620.953pylori (1)1.1830.5285.02510.0253.2631.1609.176GA−0.3560.1525.50210.0190.7010.5210.943 Multivariate logistic regression analysis on predictors of HOMA-IR ≥2.5 In this study, we investigated the relationship between H. pylori seropositivity and pregnancy outcomes including preeclampsia, preterm birth, need for insulin therapy, LGA, and SGA and we found no statistically significant association between H. pylori seropositivity and negative pregnancy outcomes [Table 3]. Table 3Pregnancy outcomes based on H. pylori seropositivityPregnancy outcomesH. pylori IgG seropositivity P Yes Frequency (%)No Frequency (%)Preeclampsia8 (12.9%)5 (13.2%)0.971Preterm birth9 (14.5%)4 (10.5%)0.565Need for insulin therapy15 (24.2%)11 (28.9%)0.599Delivery of LGA neonate17 (27.4%)9 (23.7%)0.679Delivery of SGA neonate1 (1.6%)1 (2.6%)0.724 Pregnancy outcomes based on H. pylori seropositivity Statistical analysis revealed that patients with HOMA-IR ≥2.5 had a significantly higher frequency of LGA (36.9% Vs. 5.7%, P ˂ 0.0001). However, HOMA-IR ≥2.5 was associated with a higher rate of need for insulin therapy for blood glucose control (32.3% Vs 14.3%), this difference was not statistically significant (P = 0.05). There was no significant association between HOMA-IR ≥2.5 and the frequency of preeclampsia (16.9% Vs 5.7%, P = 0.112), preterm birth (12.3% Vs 14.3%, P = 0.779) and SGA (0% Vs 5.7%, P = 0.053). DISCUSSION This study was conducted on pregnant women with GDM with the aim to investigate the association between H. pylori infection and insulin resistance as a modifiable factor in pregnant patients with gestational diabetes. The main finding of our study was the link between H. pylori infection and insulin resistance in pregnant women with gestational diabetes mellitus. This connection has been explored in various earlier studies regarding non-pregnant individuals. A recent meta-analysis by Azami et al.[17] including 22 case-control and cohort studies with 206911 participants, concluded that H. pylori infection was associated with insulin resistance. The study by Alshareef et al.[15] on 162 pregnant Sudanese women was the first and only study to investigate the association between H. pylori seropositivity and insulin resistance in pregnancy. To our knowledge, this is the first study that investigated the relationship between H. pylori infection and insulin resistance in pregnant women with gestational diabetes mellitus. The frequency of H. pylori infection in the present study was found to be 62%, which is consistent with previous studies that have shown a higher prevalence of this infection in developing countries and among pregnant women. Alshareef et al.[15] conducted a cross-sectional study involving 166 Sudanese pregnant women and reported that 109 (65.7%) of them were H. pylori IgG seropositive. Azami et al.,[4], in their systematic review, reported the global prevalence of H. pylori infection among pregnant women to be 46%, with the lowest prevalence of 25% in Europe and the highest prevalence of 62% in South America. Our research findings suggest that patients who tested positive for H. pylori IgG had higher levels of fasting insulin compared to those who tested negative. Furthermore, the frequency of Homa-IR ≥2.5, which is an indicator of insulin resistance, was observed to be higher in patients with H. pylori-positive results. Another study by Esheba et al.[18] investigated 80 non-obese and nondiabetic individuals and found that H. pylori-positive patients had higher fasting insulin levels and Homa-IR as compared to the negative groups.[18] A study by Aydemir et al.[19] on 63 non-pregnant patients of both genders (36 H. pylori infected and 27 non-infected) found that H. pylori infection was associated with a higher HOMA-IR level (1.73 ± 1.1 vs. 2.56 ± 1.54, P < 0.05). Chen et al.[20] found that H. pylori-infected patients had a higher frequency of HOMA-IR >2.5 compared to non-infected patients (27.9% vs. 21.5%, P = 0.044) in their study of 811 patients. On the other hand, Alshareef et al.[15] found no association between H. pylori infection and QUICKI as an indicator of insulin resistance in their study on pregnant women. This difference may be due to the study population difference. Our study enrolled all individuals diagnosed with gestational diabetes mellitus, while Alshareef’s study enrolled all pregnant women.). In concordance with the existing difference between our findings and the results of a study by Alshareef et al.[15]., in a study conducted by Vafaeimanesh et al.[21] on individuals with and without diabetes, it was found that H. pylori infection was associated with a higher rate of insulin resistance, as indicated by HOMA-IR, in both groups of patients. However, this association was statistically significant only in diabetic patients. Based on our findings, it can be hypothesized that insulin resistance in pregnancy that is mediated by some diabetogenic hormones (growth hormone, placental lactogen, and progesterone)[16] may be aggravated by H. pylori infection. Activation of pro-inflammatory substances (c-reactive protein, plasminogen activator inhibitor-1, and TNF-α), production of reactive oxygen species (ROS), alteration of ghrelin and leptin levels, increased production of lipopolysaccharides, and reduced insulin secretion were suggested mechanisms that induce insulin resistance by H. pylori.[17] We found no statistically significant differences between the H. pylori seropositive and seronegative groups regarding pregnancy outcomes like rate of preterm birth, preeclampsia, need for insulin therapy, LGA, and SGA neonates. Cardropoli et al.[22] in their prospective cohort study on 2820 pregnant women investigated the association of H. pylori seropositivity and pregnancy-related diseases and found no association between H. pylori infection and adverse pregnancy outcomes such as preeclampsia, cholestasis, LGA, and SGA. The study by Li et al.[23] on 356 pregnant women (208 nondiabetics, 86 with GDM, and 62 with pre-gestational diabetes (PGDM) patients) revealed a significant difference between H. pylori positive and negative subgroups in patients with GDM and PGDM in terms of the incidence of pregnancy-related complications (preeclampsia and premature delivery in GDM and preeclampsia, pregnancy-induced hypertension and premature delivery in PGDM group). In our study, there was no association between H. pylori infection and the incidence of preterm birth and preeclampsia. This difference between the two studies could be attributed to the difference in the incidence of this complication in the two studies (the rate of preeclampsia and preterm delivery in the current study and Li’s study were 13/100 Vs 13/86 and 13/100 vs. 18/86, respectively). The inclusion of just primigravid patients in Li’s study can explain the higher prevalence of preeclampsia, as primigravity is a risk factor for preeclampsia. Tang et al.[6] in their meta-analysis found a statistically significant correlation between H. pylori infection and adverse pregnancy outcomes such as preeclampsia, fetal growth restriction, gestational diabetes mellitus, and hyperemesis gravidarum but not spontaneous preterm labor. The observed difference can be considered as a result of the fact that in the present study, the investigation of pregnancy outcomes was carried out on people with gestational diabetes only, while Tang included all pregnant women. Our study revealed that the frequency of LGA was higher among patients with HOMA-Ir ≥2.5. This finding could be best explained by the hyperglycemia-hyperinsulinemia hypothesis (also called the Pedersen hypothesis). Based on this hypothesis, maternal hyperglycemia due to insulin resistance causes fetal hyperglycemia, increases insulin production from fetal pancreas, and finally, fetal overgrowth as insulin is a prominent growth hormone for the fetus.[24] The incidence of need for insulin therapy was higher among GDM patients with HOMA-IR ≥2.5; however, this finding was not statistically significant but has clinical importance. The insufficient insulin production by pancreatic beta cells in response to hyperglycemia caused by exaggerated hyper-insulinemia can explain such findings. CONCLUSION H. pylori infection is prevalent among patients with gestational diabetes and is associated with insulin resistance in this group of pregnant women. Confirmation of these findings in further large cohort studies in the future can help to design strategies in patient management and prevention of adverse pregnancy outcomes attributed to insulin resistance and poor blood glucose control. The association between H. pylori infection and insulin resistance in non-pregnant patients and adverse pregnancy outcomes in pregnant individuals, not specifically patients with GDM, has been investigated in numerous previous studies. This study was the first survey that investigated the association between H. pylori infection and insulin resistance in pregnant women with GDM. A limited number of participants was the main limitation of this study. Ethics approval and consent to participate The Ethics Committee of Qazvin University of Medical Sciences approved the study (IR.QUMS. REC.1399.071) and all participants provided informed consent. Conflict of interest There are no conflicts of interest.